BioMedNewsBreaks

MondayDec 20, 2021 2:19 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The highlight of this quarter was the five-year research agreement Mydecine Innovations entered with Johns Hopkins University School of Medicine… The agreement gives the company’s medical and scientific research teams the resources needed to explore things…

Continue Reading

MondayDec 20, 2021 1:57 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Advancing Core Research, Commercial Production Programs, Identifying Pipeline Expansion Opportunities

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently provided an update sharing significant milestones reached in 2021 for both of its operating arms, MINDCURE Research and MINDCURE Technology. MINDCURE Research offered several updates, including important milestones in its synthetic ibogaine manufacturing; the company is currently on schedule to provide Good Laboratory Practice (“GLP”) ibogaine to its research partners by the second quarter of 2022. In addition, a pre-clinical update from MINDCURE confirms that it intends to send ibogaine material to its pre-clinical research partner. Initially, the product will be…

Continue Reading

MondayDec 20, 2021 11:41 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in InMed’s notice of meeting and management information circular were approved. In addition, the company announced that an article discussing cannabinol (“CBN”) as a potential treatment option for glaucoma has been published in a peer-reviewed journal.…

Continue Reading

FridayDec 17, 2021 2:27 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Advancing MYCO-001 to Bring Safer, More Effective Smoking Cessation Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance,” covers Mydecine’s partnership with Dr. Matthew Johnson and Johns Hopkins University to advance its lead drug candidate MYCO-001 as a smoking cessation treatment. The company’s phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research…

Continue Reading

TuesdayDec 14, 2021 12:28 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Strategic CMO Appointment of Dr. Doron Sagman

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced its appointment of Doron Sagman, MD, FRCPC, as the company's new chief medical officer ("CMO"). Per the update, Dr. Joel Raskin, who was acting CMO, will transition into an advisory role for MINDCURE. As CMO, Dr. Sagman will play a key role in furthering MINDCURE'S mission to reinvent the mental health care model for patients and practitioners and advancing psychedelic-assisted therapy into common and accepted care. “Dr. Sagman's distinguished career in both mental health and the pharmaceutical industries…

Continue Reading

MondayDec 13, 2021 12:51 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Unearthing Breakthrough Discoveries That Will Reshape Understanding of Plant-Based Medicines

RYAH Group (CSE: RYAH) is a leading data technology company in plant-based medicine committed to providing valuable insight and transforming patient care through big data and artificial intelligence. According to a recent article, which contains excerpts from a RYAH blog post, “The company is working to unearth breakthrough discoveries that will reshape the understanding of plant-based medicines.” In the blog post, for instance, RYAH provided an overview of the United Kingdom’s legal cannabis market, observing that “market analysts continue to place high hopes on the potential of the U.K. market. Yet, in its current form, there remains significant room for…

Continue Reading

MondayDec 13, 2021 12:20 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Positioned to Benefit from Growth in CGM Market

Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health care observations. With the global continuous glucose monitoring (“CGM”) devices market expected to reach $19.04 billion in 2028 from $4.11 billion in 2020, according to an analysis by Reports and Data (https://ibn.fm/UBSIU), key companies in the space, including Nemaura Medical, are ideally positioned to benefit from this growth as they work to meet the needs of the industry. CGM devices enable tracking of blood glucose levels around the clock by monitoring the levels via sensors…

Continue Reading

FridayDec 10, 2021 12:25 pm

BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’

Mind Medicine (“MindMed”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, recently met with the United States Food and Drug Administration (“FDA”) Center for Devices and Radiological Health (“CDRH”) with consultation from the Center for Drug Evaluation and Research (“CDER”). The device pre-submission meeting that took place on Oct. 25, 2021, was concerning several key points for ongoing development of the MindMed Session Monitoring System (“MSMS”). MindMed presented the FDA with a working Indications for Use (“IFU”) statement and a development roadmap, which describe technology and infrastructure for the collection of precise, multimodal, multivalent data…

Continue Reading

FridayDec 10, 2021 11:13 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular Diagnostics, a peer-reviewed international medical journal that has an impact factor of 5.2. “We are very pleased with the publication of our technical paper on CDA cancer detection technology by a peer-reviewed international journal in the field of medicine,” said Dr. Chris Yu, AnPac Bio’s…

Continue Reading

ThursdayDec 09, 2021 2:27 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article…

Continue Reading